| Name | Title | Contact Details |
|---|
Healthworks Fitness is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Based in New York City, Kaden is a behavioral health company dedicated to solving the greatest healthcare challenges of our time with ground-breaking technology and unwavering humanity. Kaden`s first product tackles the opioid addiction crisis by positively influencing human behavior and making advanced technologies and proven treatments accessible to all so that no one has to fight opioid or any addiction alone.
Cgmp Validations is a Mission, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Omaha, Nebraska, Banyan Medical Systems, Inc. is a leading-edge medical software development and integration company dedicated to creating solutions that transform healthcare professionals` ability to access and interact with patient information. Our products and services are also designed to optimize efficiency, improve workflow, help ensure patient safety, and provide the highest levels of productivity and flexibility. As a result, we are uniquely positioned to provide healthcare professionals with the vital information they need to deliver better, more personalized healthcare to patients whether it be in the OR, clinic, or through real-time collaboration. Banyan Medical Systems healthcare services include consultation, software development and installation, training, and service support, as well as innovative custom solutions. Banyan has developed a series of integrated solutions that provide advantages not offered elsewhere, including: •Integration with all platforms, regardless of vendor •Ability to leverage current equipment and software, creating a seamless system •Scalability for easy expansion or re-design •Portability, including remote access
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.